CJC-1295 news
Regulator decisions, trial results and approvals involving CJC-1295, newest first. Each report is dated and cites the official record.
Medsafe warns New Zealanders that unapproved peptides are illegal to import, sell or use
On 21 May 2026 Medsafe, New Zealand's medicines regulator, issued a consumer advisory on unapproved peptide products and SARMs, naming BPC-157, retatrutide, TB-500 and others. It said many of these products are prescription medicines, that "for research purposes only" labels have no legal effect, and that Medsafe continues to seize them.
BPC-157, TB-500 and other peptides leave FDA's category 2 list after nominations are withdrawn
FDA's list of compounding substances that "may present significant safety risks" now has a separate section for 17 substances, including BPC-157, TB-500 and CJC-1295, whose nominations were withdrawn. The move reflects what the nominators did, not a finding by FDA that the peptides are safe. None of them is approved or on the list of substances pharmacies may compound with.